Using nanobiopsy to characterise tumour cells
Glioblastomas are the most common, and one of the most aggressive types of brain cancer found in adults. The current standard treatment involves surgery to remove as much of the tumour as possible, followed by radiotherapy and chemotherapy. Despite aggressive treatment, tumour recurrence is inevitable, highlighting the urgent need to understand why these treatments are failing.
What we don't know is whether glioblastoma cells are naturally resistant to treatment or whether treatment cause changes within the cells that make them resistant.
Using nanobiopsy to characterise glioblastoma cells
To investigate the possibility that current treatments cause changes within glioblastoma cells to make them more resistant to treatment, Dr Lucy Stead will be using a new technology called 'nanobiopsy'.
Nanobiopsy involves using a robotic nanopipette to extract tiny samples from living cells without killing them. This technology was developed by Dr Paolo Actis, co-Investigator of this research.
Using this powerful new technology, researchers are able to take multiple samples from the same cell to observe changes that occur within the cell over time and during the course of treatment.
By comparing what happens in treated versus untreated cells, this project will help us better understand how glioblastoma cells respond to treatment and, ultimately, how to more effectively kill them.